Rosuvastatin vs Medroxyprogesterone: side-by-side comparison
Rosuvastatin (HMG-CoA reductase inhibitor (statin)) and Medroxyprogesterone (Progestin) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Rosuvastatin | Medroxyprogesterone |
|---|---|---|
| Therapeutic class | HMG-CoA reductase inhibitor (statin) | Progestin |
| CAS | 287714-41-4 | 520-85-4 |
| ATC | C10AA07 | G03DA02 |
| Molecular weight | 481.54 g/mol | 344.49 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Rosuvastatin and Medroxyprogesterone share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Rosuvastatin acts by a different mechanism than Medroxyprogesterone, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Rosuvastatin: La rosuvastatine inhibe de façon compétitive l'HMG-CoA réductase, enzyme limitante de la synthèse hépatique du cholestérol. Medroxyprogesterone: La médroxyprogestérone se lie aux récepteurs de la progestérone et exerce de puissants effets progestatifs : épaississement de la glaire cervicale, inhibition de l'ovulation, amincissement de l'endomètre et réduction des…
Indications compared
Rosuvastatin: La rosuvastatine est autorisée chez l'adulte dans l'hypercholestérolémie primaire et la dyslipidémie mixte, dans la prévention des événements cardiovasculaires chez les patients à risque élevé et en prévention secondaire… Medroxyprogesterone: La médroxyprogestérone est autorisée dans l'aménorrhée, les saignements utérins anormaux d'origine hormonale, la prévention de l'hyperplasie endométriale chez la femme ménopausée recevant un estrogène, et la prévention d…
Safety profile
Rosuvastatin: Les effets indésirables fréquents comprennent myalgies, troubles digestifs, céphalées et élévation modérée des transaminases. Medroxyprogesterone: Les effets indésirables fréquents de la forme orale comprennent saignements irréguliers, tension mammaire, variations de l'humeur, rétention hydrique et prise de poids.
Questions fréquentes
Is Rosuvastatin better than Medroxyprogesterone? ▾
Rosuvastatin and Medroxyprogesterone are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Rosuvastatin and Medroxyprogesterone be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Rosuvastatin
Products with Medroxyprogesterone
Les informations publiées sur ce site sont fournies à titre documentaire et pédagogique. Elles ne remplacent pas l'avis d'un professionnel de santé qualifié.